Article Details
Retrieved on: 2024-03-25 20:06:08
Tags for this article:
Click the tags to see associated articles and topics
Summary
Abbvie's acquisition of Landos Biopharma for $138 million bolsters its inflammatory disease portfolio, gaining a new drug, NX-13, targeting ulcerative colitis and potentially Crohn’s disease amidst competition in the biopharma sector.
Article found on: finance.yahoo.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here